The US Meals and Drug Administration has cleared the Nexpowder endoscopic hemostasis system.
Nexpowder (Medtronic) makes use of a noncontact, nonthermal, nontraumatic hemostatic powder that’s sprayed by means of a catheter and that incorporates a proprietary powder-coating know-how that helps cut back clogging.
This gives improved visibility and management for treating higher gastrointestinal (GI) nonvariceal bleeding, the corporate explains in a information launch.
Nexpowder is sprayed instantly on a goal web site endoscopically by means of a catheter that connects to a twig deal with. Upon contact, it kinds a muco-adhesive, sturdy gel, with or with out blood, which degrades in 1 to three days.
As a result of it would not require CO2 or air compressors, the Nexpowder endoscopic hemostasis system “combats the inefficiency of clogged catheters and cloudy fields of imaginative and prescient with a proprietary hydrophilic polymer to allow managed supply, reduce catheter clogging and preserve endoscopic visibility,” the corporate explains.
In testing, Nexpowder demonstrated a 94% speedy hemostasis price and a 3.7% rebleeding price.
Greater than 1 million endoscopic hemostasis procedures are carried out annually in the US. Higher GI bleeding is among the commonest causes, accounting for 75% of all acute GI bleeding instances, based on Medtronic.
For extra information, comply with Medscape on Fb, Twitter, Instagram, and YouTube.